June 26, 2026 -- NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto, Japan; President, Toru Nakai) has entered into an option agreement with Elixirgen Therapeutics, Inc. (Elixirgen; Headquarters, Baltimore, MD; CEO, Aki Ko) under which Nippon Shinyaku may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the treatment of Duchenne

The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said. Merck KGaA has agreed to buy Bio-Techne for $11.3 billion to acquire consumables and equipment used in activities including the production of advanced therapeutics. Bio-Techne provides products for use across drug discovery, development and manufacturing, as well as for diagnostics. The development and manufacturing of advanced therapeutics is the smallest

June 25, 2026 -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, Oblenio Bio (“Oblenio”), has successfully closed an oversubscribed $62 million Series B financing round. The round was led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor Aditum Bio. This milestone significantly advances the clinical development of LBL‑051, Oblenio’s sole asset – a CD19×BCMA×CD

June 22, 2026 -- Hamlet BioPharma AB (publ) today announced the signing of a clinical trial agreement with the University of Iowa, one of the leading U.S. centers for bladder cancer research and therapy. The new study advances the clinical development of Alpha1H, a human breast milk derived treatment for bladder cancer, to include Carcinoma In Situ (CIS); a severe surface-spreading and therapy-resistant form of bladder cancer where patients may need to remove their bladders to avoid systemic dis

AbbVie is making its biggest acquisition in years in a bid to expand its portfolio of autoimmune disease drugs, announcing on Monday plans to buy Apogee Therapeutics for nearly $11 billion. The pharmaceutical giant will pay $135.11 per share for Apogee, a roughly 49% premium to the biotechnology company’s closing price on Friday. The acquisition should close in the third quarter of 2026, pending approvals from shareholders and regulatory agencies. The Financial Times first reported news of a pe

June 22, 2026 -- TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for immune-mediated inflammatory diseases, today announced that it has entered into an exclusive license agreement with Bionyra Pharma, a newly launched clinical-stage biopharmaceutical company, for TL-001, an anti-TL1A monoclonal antibody, and TL-003, a TL1A × IL-23p19 bispecific antibody. Under the terms of the agreement, Bionyra has

Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination ta

June 22, 2026 -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervou

June 12, 2026 -- Transcend Therapeutics today announced the completion of its acquisition by Otsuka America Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. (Otsuka), marking a significant milestone in Transcend's mission to develop rapid-acting treatments for neuropsychiatric diseases, including post-traumatic stress disorder (PTSD). The acquisition was originally announced on March 27, 2026. With the completion of the transaction, Transcend is now a wholly owned subsidiary of Otsuka Amer

June 12, 2026 -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). According to the agreement, Simcere Pharmaceutical will fund the exploratory research of this first-in-class novel molecule. Upon successful completion, Simcere wil